Innovent's KRAS G12C inhibitor, Dupert® (Fulzerasib tablets), has received market approval from the China National Medical Products Administration. The approval pertains to adult patients with advanced non-small cell lung cancer harboring the KRAS G12C mutation and who have received at least one systemic therapy.
Dupert is the first approved KRAS G12C inhibitor in China, filling a 40-year gap in domestic targeted therapy for KRAS G12C mutations.
With the launch of the new drug, Innovent's Shanghai office in the Minhang area of Hongqiao International Central Business District has also been officially inaugurated.
Innovent launches its Shanghai office in the Minhang area of Hongqiao International CBD. [Photo/WeChat ID: minhangnews]
In Hongqiao Qianwan area, adjacent to Innovent's Shanghai R&D Center, work on a series of projects invested by medical-related enterprises is progressing rapidly.
More than 10 leading biopharmaceutical companies in the area have attracted nearly 100 upstream and downstream enterprises. The Hongqiao Qianwan area is becoming a new hub for the biopharmaceutical industry in the Yangtze River Delta (YRD) region, said a spokesperson from the South Hongqiao Group.
The Innovent Shanghai R&D Center has commenced operations, marking a crucial step forward in the enterprise's global strategic layout.
"Globalization is our mission. We hope that through our efforts, we can not only lower drug prices and enable more people to access medication, but also narrow the gap between China's biopharmaceutical R&D level and international standards," said Zhao Lei, vice-president of Innovent. Locating the center in the Hongqiao International CBD is a vital step for Innovent, as the district encourages innovation in the biopharmaceutical field and supports the development of cutting-edge technologies such as new drug research and development.
